|Ms. Carrie L. Bourdow||Pres, CEO & Director||1.62M||N/A||1963|
|Dr. Mark A. Demitrack||Sr. VP & Chief Medical Officer||784.28k||N/A||1958|
|Dr. Howard A. Rockman M.D.||Scientific Founder, Consultant and Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. John P. Hamill||VP of Fin.||N/A||N/A||1964|
|Erin Clark||Sr. Director of Corp. Strategy & Investor Relations||N/A||N/A||N/A|
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.